Carcinoma epidermoide conjuntival: respuesta paradójica al colirio interferón

Mata, Elena; Conesa, Eduardo; Castro, M.; Martínez, L.; Pablo, Carmen de; González, Marta

doi:10.1016/j.oftal.2012.12.010

Cited by 8 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While an efficient immune system has been advocated as a requisite for IFN-α2b efficacy [ 138 , 139 ], the presence of HPV infection does not seem to influence the response to the treatment [ 140 ]. In case of HIV-related immunosuppression, clinicians should prefer non-immunomodulating agents, such as 5-FU or MMC, in association with the highly active anti-retroviral therapy (HAART) protocol, even though the role of HAART in OSSN regression is still being debated [ 37 , 141 ].…”

Section: Treatmentmentioning

confidence: 99%

Clinical Management of Ocular Surface Squamous Neoplasia: A Review of the Current Evidence

et al. 2018

View full text Add to dashboard Cite

Ocular surface squamous neoplasia (OSSN) is the most common non-pigmented malignancy of the ocular surface and is represented in a wide range of histologic diagnoses, ranging from mild epithelial dysplasia to invasive squamous carcinoma. Although surgical excision is still the gold standard for OSSN treatment, interest in conservative medical approaches is steadily growing. We have reviewed all of the literature on OSSN published in English in the MEDLINE database up to May 2018, using the keywords “ocular surface squamous neoplasia,” “squamous conjunctival carcinoma,” and “conjunctival carcinoma in situ,” with the aim to provide a comprehensive review of the most recent evidence on this distinct clinical entity.

show abstract

Section: Treatmentmentioning

confidence: 99%

Clinical Management of Ocular Surface Squamous Neoplasia: A Review of the Current Evidence

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Therefore, serology for HIV is recommended in patients with OSSN before commencing treatment with topical IFNα 2b . 85 …”

Section: Immunotherapy In Ossn and Related Concerns In Hiv Patientsmentioning

confidence: 99%

Ocular surface squamous neoplasia in HIV-infected patients: current perspectives

Rathi¹,

Kapoor²,

Kaliki³

2018

HIV

View full text Add to dashboard Cite

Ocular surface squamous neoplasia (OSSN) refers to a spectrum of conjunctival and corneal epithelial tumors including dysplasia, carcinoma in situ, and invasive carcinoma. In this article, we discuss the current perspectives of OSSN associated with HIV infection, focusing mainly on the epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of these tumors in patients with HIV. Upsurge in the incidence of OSSN with the HIV pandemic most severely affected sub-Saharan Africa, due to associated risk factors, such as human papilloma virus and solar ultraviolet exposure. OSSN has been reported as the first presenting sign of HIV/AIDS in 26%–86% cases, and seropositivity is noted in 38%–92% OSSN patients. Mean age at presentation of OSSN has dropped to the third to fourth decade in HIV-positive patients in developing countries. HIV-infected patients reveal large aggressive tumors, higher-grade malignancy, higher incidence of corneal, scleral, and orbital invasion, advanced-stage T4 tumors, higher need for extended enucleation/exenteration, and increased risk of tumor recurrence. Current management of OSSN in HIV-positive individuals is based on standard treatment guidelines described for OSSN in the general population, as there is little information available about various treatment modalities or their outcomes in patients with HIV. OSSN can occur at any time in the disease course of HIV/AIDS, and no significant trend has been discovered between CD4 count and grade of OSSN. Furthermore, the effect of highly active antiretroviral therapy on OSSN is controversial. The current recommendation is to conduct HIV screening in all cases presenting with OSSN to rule out undiagnosed HIV infection. Patient counseling is crucial, with emphasis on regular follow-up to address high recurrence rates and early presentation to an ophthalmologist for of any symptoms in the unaffected eye. Effective evidence-based interventions are needed to allow early diagnosis and treatment, as well as prevention of the disease.

show abstract

“…These can aff ect the entire thickness of the epithelium (carcinoma in situ) or cross the basement membrane and invade the stroma. Genetic factors, Ultraviolet B radiation, human papillomavirus (HPV) 16 and 18, human immunodefi ciency virus (HIV) (Mata et al, 2014), intense smoking and exposure to petroleum products (Scott, Karp and Nuovo, 2002;Karp et al, 2010) have been associated with its etiology.…”

Section: Introductionmentioning

confidence: 99%

Management of Ocular Surface Squamous Neoplasia with Topical and Intralesional Interferon Alpha 2B in Mexicans

et al. 2018

View full text Add to dashboard Cite

Introduction: Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm and it can originate from the conjunctiva and/ or corneal epithelium. Since the rate of recurrence after surgical excision is high, chemotherapeutic and immunotherapeutic agents such as interferon alpha-2b (IFN α-2b) have been used for its treatment. Objective: Our objective is to describe the demographic variables of patients with OSSN treated with IFN α-2b and to describe the outcomes of its use in Mexican patients, treated between 2011 and 2017 at Instituto de Oftalmología Fundación Conde de Valenciana. Materials and Methods: This is a non-randomized retrospective interventional case series. We reviewed the files of patients older than 18 years, with clinical and/or histopathological diagnosis of OSSN, treated with IFN α-2b alone or in combination with surgery, with a minimum of 6 months follow-up. We studied demographic variables, such as gender, age, eye affected and associated risks factors; we also studied the type of therapy with interferon (topical, intralesional and/or associated with surgery), time of treatment, time of follow up, recurrences and complications. Results: A total of 39 patients were included. The mean age of diagnosis was 61 ± 16 years and OSSN was more frequent in males (64.1% of cases). Most of the cases (43.6%) had no identifiable risk factors. The mean time of IFN α-2b treatment was 5 ± 2 months, being higher in the intralesional group (6.5 months) than in the topical group (4.2 months). The clinical resolution with the use of IFN α-2b was evidenced between 0.5 and 10 months, being achieved in 87.1% of the patients. Conclusions: The use of IFN α-2b is effective for the treatment of OSSN with a high success rate (87.1%) and a low incidence of relapse (5 cases), with no reported complications during follow up.

show abstract

Carcinoma epidermoide conjuntival: respuesta paradójica al colirio interferón

Cited by 8 publications

References 8 publications

Clinical Management of Ocular Surface Squamous Neoplasia: A Review of the Current Evidence

Clinical Management of Ocular Surface Squamous Neoplasia: A Review of the Current Evidence

Ocular surface squamous neoplasia in HIV-infected patients: current perspectives

Management of Ocular Surface Squamous Neoplasia with Topical and Intralesional Interferon Alpha 2B in Mexicans

Contact Info

Product

Resources

About